Objective. Although generally classified within the group of inflammatory myopathies, JDM displays many pathological features of vasculitis. Previous work has shown that AECA are abundant in other forms of vasculitis. We therefore investigated whether such antibodies might also be detected in JDM.
Introduction
JDM is the most common form of inflammatory myopathy in children [1] . Although classified as a myopathy, involved tissues in JDM are characterized by prominent vascular and perivascular inflammation that contributes directly to the clinical features of the disease [2] . Indeed, one of the earliest descriptions of JDM in the English language, the classic paper by Banker and Victor, described JDM as '. . . systemic angiopathy . . . of childhood' [3] . Thus, JDM can also be regarded as a form of vasculitis.
Autoantibody expression involving a broad spectrum of autoantigens is a well-documented feature of JDM [1, 4] . These autoantibodies have specific clinical associations, but their relationship to disease pathology remains unclear. These autoantibodies are typically identified by immunoprecipitating protein or DNA from radiolabelled HeLa or K562 cell extracts and double immunodiffusion [1] , and thus the actual in vivo cellular targets of these autoantibodies remain unclear. We have recently demonstrated that several forms of vasculitis are associated with autoantibody responses to endothelial cells [5, 6] , and the presence or titre of these autoantibodies may serve as biomarkers of disease or to monitor disease activity. The studies described here were undertaken to determine whether the endothelium in JDM might similarly be targeted by autoantibodies.
Methods

Patients
Plasma of patients with JDM (n = 39) were collected from the University of Oklahoma Pediatric Rheumatology clinic between 2007 and 2011. The mean (S.D.) age of the patients with JDM (28 females and 11 males) was 9 (4) years, with a range of 316. Children with active JDM had disease durations ranging from 4 months to 3 years, and were being treated with weekly injectable MTX (25 mg/m 2 body surface area), daily oral steroids (<1.0 mg/kg/day) and pulse methylprednisolone given at a dose of 500 mg/m 2 body surface area for intervals ranging from once a week to once a month. Children with inactive disease who were on maintenance therapy with weekly injectable MTX were 1148 months post-diagnosis. Active disease was defined as the presence of any of the following: JDM-associated rash, periungual capillary abnormalities (dilatation, dropout) or elevations in serum levels of creatine phodphokinase or aldolase. Elevations of aspartate amino transferase or alanine amino transferase were considered signs of active disease if MTX-associated hepatic injury was excluded based on clinical grounds and normal serum levels of gamma glutamyl transferase. Plasma of patients with JIA (n = 15, 13 females and 2 males) and healthy children (n = 20, 11 females and 9 males) were collected from All cells were cultured in the media and supplements as described previously [5] . Cells at passages 14 were harvested and stored at À80 C until use for 2D gel electrophoresis (2DE) or SDSPAGE.
2D gel electrophoresis 2DE was conducted as described previously [5] with the following modifications. Protein (400 mg) from the harvested HAEC was applied onto Immobiline DryStrip gels (pH3.010.0; GE Healthcare, Uppsala, Sweden). After electrophoresis, one gel was used for Coomassie Brilliant Blue R-250 staining and the other gel was used for transfer of the separated proteins onto a nitrocellulose membrane for western blotting (WB). SDSPAGE SDSPAGE was conducted as described previously [5] . To detect AECA, proteins extracted from HAEC, HMVEC-D, AoAF, HAoSMC and SkMC were used for SDSPAGE and WB. 20 mg of extracted proteins were applied to 12.5% SDSPAGE gels, after which the separated proteins on the gels were transferred onto nitrocellulose membranes for WB.
Western blotting WB after SDSPAGE or 2DE was performed as described previously [5] . Plasma from patients with JDM were used for SDSPAGE (five samples) or 2DE (three samples) at a final dilution of 1:100 (1:500 for each donor in SDSPAGE) or that of 1:100 (1:300 for each donor in 2DE). Then the bound antibodies were reacted with horseradish peroxidase-conjugated goat anti-human IgG diluted 1:2000. Finally, the bound IgG antibodies were visualized using diaminobenzidine.
Protein identification
In-gel digestion was performed as described previously [5] . Analysis of peptides was carried out using an liquid chromatography/tandem mass spectrometry (LC-MS/MS) system, which consisted of a nano ultra high performance liquid chromatography-electrospray ionization-quadrupole time-of-flight system (maXis-4 G-CPR; Bruker Daltonics, Billerica, MA, USA). A L-column octadecylsilanebonded silica [L-column ODS], 0.075 Â 150 mm, 3 mm particle size, Chemicals Evaluation Research Institute (CERI), Tokyo, Japan] was used. The eluted peptides were directly electro-sprayed into the spectrometer, with MS/MS spectra acquired in a data-dependent mode. Database searches in the SwissProt database were performed using the Mascot 2.5.1 (Matrix Science, Boston, MA, USA) incorporated into ProteinScape3.1 (Bruker Daltonics, Billereica, MA).
ELISA ELISA was conducted as described previously [5] . To detect antibodies to heat shock cognate 71 kDa protein (HSC70) in plasma, each well of an ELISA plate was coated with 0.125 mg of HSC70 (StressMarq Biosciences, Victoria, BC, Canada) in a carbonate buffer (50 mM sodium carbonate, pH 9.6). The plasma diluted 1:200 with 10% Block Ace were reacted with the coated recombinant proteins. Optical density at 490 nm was measured by a microplate reader. The average plus 2 S.D. among the group of healthy donors was defined as 100 arbitrary binding units and was used as a cut-off point for determining reactivity to HSC70.
Statistics
Fisher's exact test was used to compare the frequency of each antibodies between each of the phenotypes and JDM disease states.
Results
Detection of antibodies in patients with JDM
To select the best antigen source, we first detected autoantibodies in plasma from patients with JDM, both active patients without treatment and inactive patients (off medication) using proteins extracted from five different cells by WB [ Fig. 1A (a) and (b) ]. Multiple antigens were detected in each cell line, in particular HAEC. Among three types of cells derived from aorta (HAEC, AoAF and HAoSMC), staining patterns appeared to differ most between the HAEC and the other cell lines. We also noted distinct differences in the staining patterns between patients with active JDM and patients with inactive JDM. In plasma from patients with inactive JDM, differences in staining patterns between each cell line were not significant. Based on these results, HAEC were used for 2DE to facilitate identification of specific antigens. We limited 2DE studies to plasma samples from active patients without treatment.
Candidate antigens for AECA detected in JDM by 2DE-WB To detect JDM-specific antigens on HAEC, results of 2DE-WB using plasma from untreated JDM patients with active disease [ Fig. 1B (a) ] were compared with results from plasma from healthy children [ Fig. 1B (b) ]. Five candidate protein spots were detected in 2DE-WB [arrows, Fig. 1B  (a) and C]. Twenty-two proteins from five protein spots recovered from 2DE gels were identified using mass spectrometry (Table 1) .
Antibodies against chaperone or co-chaperone proteins identified in patients with JDM Using pathway analysis, 17 of the 22 candidate target antigens for AECA in JDM were predicted to interact with chaperone proteins involved in antigen processing and presentation. Among the seven chaperone or cochaperone proteins were HSC70, HSP 90-beta (HS90B) and stress-induced-phosphoprotein 1, a protein that mediates the association of HSC70 and HSP90. IgG autoantibodies to HSC70 were detected by ELISA in 23% of the patients with JDM (n = 39; Fig. 1D ). However, 50% of the untreated JDM patients with active disease (n = 10) had anti-HSC70 antibodies, in contrast to 7% (P < 0.05) of the patients with JIA (n = 15) and 5% (P < 0.01) of control children (n = 20). Among treated patients with active disease (n = 15), 13% had detectable anti-HSC70 antibodies, while 14% of the patients with inactive disease (n = 14) had detectable anti-HSC70 antibodies. The frequency of anti-HSC70 antibodies shown was not significantly different with regard to age or sex. On the other hand, IgG autoantibodies to HS90B were detected in 6% of the patients with JDM (n = 31) and IgG autoantibodies to stressinduced-phosphoprotein 1 were not detected patients with JDM (data not shown).
Discussion
Despite the prominence of the vascular features of JDM, few investigations have focused on this aspect of the pathobiology of the disease. Thus, the question of how and why blood vessels within the skin and musculature (and other sites) of patients with JDM become targets of immune attack remains unanswered.
In the current paper, we used a proteomic approach to address this question. Specifically, we asked whether endothelial cells might be targets of autoantibodies, a plausible hypothesis given that at least one study has demonstrated the presence of both IgG and complement proteins within the vessel walls of children with JDM [8] , although a recent study has not duplicated this finding [9] . We found that a broad spectrum of AECA could be identified in plasma samples from children with JDM (Table 1) . These antibodies were more commonly found in children with active, untreated JDM and were rare in children with polyarticular-onset JIA.
These antibodies were not randomly directed toward cellsurface proteins, but seemed to be directed toward proteins involved in antigen processing and stress response (e.g. HSC70). This finding suggests that at least some AECA may play a regulatory role, modifying the processing of antigens, long recognized as an important function of endothelium [10] . In support of a regulatory role for the autoantibodies are the findings of De Paep et al. [11] , who reported that, in inflammatory myopathies in adults, HSP70, an homologous protein, is expressed in injured muscle fibers and may be involved in muscle repair and regeneration. This finding is consistent with the report by Miš unová et al. [12] demonstrating increased levels of HSP70 proteins in serum of adult patients with inflammatory myopathies. Thus, it is possible that the presence of HSC70 antibodies is a response to damaged muscle fiber rather than a primary mechanism of injury. A growing body of evidence supports the idea that type-1 IFN-induced muscle damage may be the primary mechanism of JDM [13, 14] .
Rider et al. have shown that specific autoantibodies in childhood inflammatory myopathies are associated with distinct clinical phenotypes, disease complications and/ or clinical outcomes. Our patient numbers are too small to determine whether such associations exist for AECA in JDM, and our patient population was homogeneous compared with the broad clinical spectrum of childhood inflammatory myopathies [1] . Studies of a larger, clinically heterogeneous population will be required to determine whether there are associations between AECA and specific clinical phenotypes or outcomes.
Our data suggest that antibodies against HSC70, which was one of the antigens identified by mass spectrometry, might be a useful diagnostic biomarker. The autoantigens we identified in JDM did not overlap with what we have seen in systemic vasculitis using a similar approach [5] . There are also reports of autoantigens for AECA in patients with SLE [1517] . Autoantibodies against HSP family proteins such as HSP60 [15] and HSP90 [16] , but not HSP70 [16] , were detected by ELISA in SLE. Using ELISA assays, we identified anti-HSC70 in 5 of the 10 samples of children with newly diagnosed, untreated JDM and in fewer than 5% of children with polyarticular JIA. If these findings are corroborated in a larger cohort of patients, anti-HSC70 would have significantly better specificity than other screening tests commonly used in primary care settings, for example, ANA [18] .
In conclusion, we have demonstrated the presence of a broad spectrum of previously unrecognized AECA in children with JDM. Larger studies are needed to determine the clinical significance of these antibodies and/or their utility and diagnostic or prognostic biomarkers. 
